ReviewMolecular biology reports2026
Emerging RNA biomarkers for diabetes: Mechanistic insights and clinical relevance.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a complex, multifactorial metabolic disorder characterized by chronic hyperglycemia and progressive organ dysfunction. Conventional diagnostic and prognostic markers such as fasting glucose and glycated hemoglobin provide limited insight into disease heterogeneity, early molecular changes, and individualized risk of complications. In recent years, RNA-based biomarkers have emerged as powerful tools for capturing dynamic regulatory processes underlying diabetes onset, progression, and therapeutic response. These biomarkers include messenger RNAs (mRNAs), microRNAs (miRNAs), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and transfer RNA-derived fragments (tRFs), which collectively orchestrate gene expression, metabolic signaling, immune modulation, and cellular stress responses. This review comprehensively examines the landscape of RNA-based biomarkers in diabetes, highlighting their mechanistic relevance, detection platforms, clinical utility, and translational challenges. We discuss how regulatory RNA networks reflect beta-cell dysfunction, insulin resistance, inflammation, and tissue-specific pathology, and how their integration into liquid biopsy approaches and computational frameworks may redefine precision diagnostics and personalized diabetes care.
Indexed as
Identifiers
42461341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.